Published Technical Disclosure Archive

Intelligent Extracorporeal Blood Treatment Systems

Publication ID: 24-11857715_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Extracorporeal Blood Treatment Systems,” Published Technical Disclosure No. 24-11857715_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857715_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,715.

Summary of the Inventive Concept

The present invention integrates AI, IoT, blockchain, and nanomaterials with extracorporeal blood treatment devices to create a more efficient, patient-centric, and data-driven system.

Background and Problem Solved

The original patent disclosed an extracorporeal blood treatment apparatus with a blood-warming device. However, it lacked advanced data management, real-time monitoring, and adaptive control capabilities. The new inventive concept addresses these limitations by incorporating synergistic technologies to enhance patient safety, treatment efficacy, and data integrity.

Detailed Description of the Inventive Concept

The inventive concept comprises an extracorporeal blood treatment device, a blood warmer, and an extracorporeal blood circuit. Additionally, it integrates a blockchain-based data management system for secure and transparent treatment data tracking, an IoT-enabled sensor for real-time monitoring of priming parameters, and an AI-powered control system for optimizing treatment parameters based on patient data. Furthermore, a nanomaterial-based coating can be applied to reduce blood clotting and improve biocompatibility. The system enables personalized treatment, predictive maintenance, and remote monitoring, improving overall treatment outcomes.

Novelty and Inventive Step

The new claims introduce the innovative combination of AI, IoT, blockchain, and nanomaterials with extracorporeal blood treatment devices, providing a synergistic system that enhances patient safety, treatment efficacy, and data integrity. This integration is non-obvious and novel compared to the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, IoT protocols, or blockchain platforms. Variations may involve integrating additional sensors, actuators, or data analytics tools to further enhance the system's capabilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the medical device industry, particularly in the areas of extracorporeal blood treatment, patient monitoring, and personalized medicine. The target market includes hospitals, clinics, and medical research institutions.

CPC Classifications

SectionClassGroup
A A61 A61M1/369
A A61 A61M1/3623
A A61 A61M1/3626
A A61 A61M1/3627
A A61 A61M1/3643
A A61 A61M39/28
A A61 A61M2205/3344
A A61 A61M2205/36

Field of Art

Medical device engineering, specifically extracorporeal blood treatment systems, involving complex medical instrumentation, sensor integration, data management, and patient monitoring technologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer with expertise in medical device design, proficient in IoT technologies, data analytics, sensor integration, and familiar with emerging technologies like blockchain and AI applied to medical systems

Obviousness Rationale

A PHOSITA would recognize that integrating advanced digital technologies like AI, IoT, and blockchain into existing extracorporeal blood treatment systems represents a predictable evolution of medical device design. The source patent's foundational blood treatment apparatus provides a clear technical framework that can be naturally extended through contemporary digital enhancement techniques. The proposed variations represent logical technological progressions that would be obvious to implement given the existing technical infrastructure and emerging digital health trends.

Obvious Combinations & Variations

Source Patent Element
Extracorporeal blood treatment apparatus with blood circuit and return lines
PTD Variation
Adding blockchain-based data management system for tracking treatment data
Obviousness Reasoning
Implementing digital record-keeping is a known technique in medical device design, representing a predictable application of existing data management technologies to improve treatment documentation and transparency
Source Patent Element
Blood treatment device with control mechanisms
PTD Variation
Integrating AI-powered control system for optimizing treatment parameters
Obviousness Reasoning
Applying machine learning to medical device parameter optimization is a well-established approach, representing a straightforward technological enhancement that a skilled practitioner would find obvious
Source Patent Element
Extracorporeal blood circuit with return lines
PTD Variation
Implementing IoT-enabled sensors for real-time monitoring of priming parameters
Obviousness Reasoning
Adding networked sensor technologies to medical devices is a predictable evolution in medical instrumentation, providing enhanced monitoring capabilities through known technological integration techniques
Source Patent Element
Blood treatment apparatus with heating components
PTD Variation
Applying nanomaterial-based coating to reduce blood clotting and improve biocompatibility
Obviousness Reasoning
Utilizing advanced materials to enhance medical device performance is a standard design approach, representing a finite and predictable solution to improving device functionality
35 U.S.C. § 103 Summary: Based on US Patent 11857715, the present publication demonstrates that the integration of digital technologies into extracorporeal blood treatment systems would be obvious to a person having ordinary skill in the art. The disclosed variations represent predictable technological extensions that combine known techniques in medical device design, IoT integration, and data management, thereby rendering potential patent claims obvious and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,715
TitleExtracorporeal blood treatment apparatus
Assignee(s)Gambro Lundia AB